Compare SABS & SBMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | SBMT |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 242.1M |
| IPO Year | 2020 | 2026 |
| Metric | SABS | SBMT |
|---|---|---|
| Price | $3.01 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $11.64 | ★ $20.13 |
| AVG Volume (30 Days) | ★ 672.8K | 159.9K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $5.19 |
| 52 Week High | $5.15 | $9.48 |
| Indicator | SABS | SBMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 44.95 |
| Support Level | $2.44 | $6.06 |
| Resistance Level | $4.03 | $7.80 |
| Average True Range (ATR) | 0.23 | 0.54 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 38.33 | 63.87 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.